Milton Hom
Corneal and Contact Management · Azusa, CANPI 1326158478
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $502,775 of the $762,340 with a category attached, or 66.0%. 18 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 51.8% of the total. Reporting peaked in 2023 at $347,209 and has fallen 89.5% since, to $36,373 in 2025. Among corneal and contact management clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $1527.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$395K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$170K
- AbbVie$150K
- Harrow Eye, LLC$26K
- Novartis$5K
- Thea Pharma Inc.$2K
- plus $14K from 12 others
Across 67 payments — averaging $11,996 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$531K
- Novartis$110K
- Kala Pharmaceuticals, Inc.$103K
- Shire North American Group Inc$43K
- Bausch Health US, LLC$17K
What the payments were for
- Consulting fees$208,57127%
- Speaking & faculty fees$502,77566%
- Travel & lodging$8,4691%
- Food & beverage$10,0071%
- Education$32,5004%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 37 | $395,222 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 71 | $170,017 |
| AbbVie(2 entities) | 177 | $149,910 |
| Harrow Eye, LLC | 24 | $26,030 |
| Novartis | 31 | $4,611 |
| Thea Pharma Inc. | 12 | $2,410 |
| Dompe US, Inc. | 1 | $2,400 |
| Sun Pharmaceutical Industries Inc. | 98 | $2,133 |
| Oyster Point Pharma, Inc. | 4 | $1,822 |
| Eyevance Pharmaceuticals LLC | 3 | $1,540 |
| Topcon Healthcare, Inc. | 1 | $1,500 |
| Carl Zeiss Meditec, Inc. | 4 | $1,306 |
| Alcon | 7 | $1,196 |
| Kala Pharmaceuticals, Inc. | 14 | $1,056 |
| Shire North American Group Inc | 8 | $967 |
| Tarsus Pharmaceuticals, Inc. | 5 | $147 |
| Mallinckrodt Enterprises LLC | 1 | $38 |
| Aerie Pharmaceuticals, Inc. | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$762,340 in reported general payments places this provider in the 95th percentile of 140 corneal and contact management providers in California.
See all corneal and contact management providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 31 | $13,288 |
| Epinastine Hcl | 66 | $6,179 |
| Latanoprost | 40 | $505 |
| Azelastine Hcl | 15 | $446 |
Paid to pharmacies, not to this prescriber.
Other corneal and contact management in Azusa
- Kambiz SilaniBeverly Hills$123K
- Gloria ChiuLos Angeles$80K
- John GellesSunnyvale$37K
- Nathan SchrammCosta Mesa$34K
- Jasdeep SoniBakersfield$26K
- Arti ShahCerritos$20K
- Gregory TomSan Ramon$16K
- Jay MashoufSan Diego$14K
- Ruth TangIrvine$13K
- Jim ChanArcadia$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.